HITIQ Raises $925,000 at 2.2 Cents Per Share with Attaching Options
HITIQ Limited has successfully raised $925,000 through an oversubscribed placement, issuing shares at a discount and attaching listed options to support its concussion management technology's commercialisation.
- Oversubscribed placement raising $925,000 at 2.2 cents per share
- Shares issued at an 8.3% discount to recent closing price
- One listed option attached for every two shares subscribed
- Directors’ participation subject to shareholder approval in January 2026
- Funds earmarked for development, commercialisation, and working capital
Placement Details and Pricing
HITIQ Limited (ASX, HIQ), a pioneer in concussion management technology, has completed an oversubscribed placement raising approximately $925,000 before costs. The company issued 42,045,455 ordinary shares at $0.022 each, representing a discount of 8.3% to the closing price on 1 December 2025 and an 11.9% discount to the 30-day volume weighted average price. This pricing strategy reflects a balance between attracting new investment and maintaining shareholder value.
Strategic Investor Support and Shareholder Engagement
The placement attracted both new and existing sophisticated investors, signaling continued confidence in HITIQ’s growth trajectory. Notably, directors Tony Toohey and James Barrie have also subscribed, though their participation awaits shareholder approval at a general meeting scheduled for January 2026. This step underscores the company’s commitment to governance and transparency.
Use of Funds and Commercial Momentum
Funds raised will be deployed to advance HITIQ’s ongoing development and commercialisation activities, particularly around its flagship PROTEQT™ instrumented mouthguard. This product, designed to enhance athlete safety by delivering real-time concussion impact detection and risk assessment, has been gaining traction in both elite and community sports markets. The capital injection aims to solidify HITIQ’s financial position heading into 2026, supporting both product innovation and operational needs.
Options Attached to Placement Shares
In addition to the shares, the placement includes one attaching listed option for every two shares subscribed. These options are exercisable at $0.022 and expire on 30 December 2028, providing investors with potential upside participation aligned with the company’s long-term growth prospects.
Market Position and Outlook
HITIQ’s recent capital raising follows a rights issue earlier in 2025 and reflects sustained investor interest amid growing commercial momentum. The company’s focus on concussion management technology positions it well within the expanding sports safety sector, where demand for innovative protective solutions continues to rise globally. The fresh capital is expected to underpin HITIQ’s strategy as it scales its PROTEQT™ system and explores new market opportunities.
Bottom Line?
With fresh capital secured, HITIQ is poised to accelerate its commercial push, but investor eyes will be on upcoming shareholder approvals and execution milestones.
Questions in the middle?
- Will shareholder approval for director participation proceed smoothly in January 2026?
- How will the dilution impact existing shareholders given the placement and attached options?
- What specific commercial milestones will HITIQ target with the new funds in 2026?
